Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 262

1.

Paediatric haemolytic uraemic syndrome related to Shiga toxin-producing Escherichia coli, an overview of 10 years of surveillance in France, 2007 to 2016.

Bruyand M, Mariani-Kurkdjian P, Le Hello S, King LA, Van Cauteren D, Lefevre S, Gouali M, Jourdan-da Silva N, Mailles A, Donguy MP, Loukiadis E, Sergentet-Thevenot D, Loirat C, Bonacorsi S, Weill FX, De Valk H, Réseau Français Hospitalier de Surveillance du Shu Pédiatrique.

Euro Surveill. 2019 Feb;24(8). doi: 10.2807/1560-7917.ES.2019.24.8.1800068.

2.

Successful treatment of a Streptococcus pneumoniae-associated haemolytic uraemic syndrome by eculizumab.

Jeantet G, Pernin V, Brunot V, Roccabianca A, Macombe A, Szwarc I, Klouche K, Loirat C, Mourad G, Frémeaux-Bacchi V, Le Quintrec M.

Clin Kidney J. 2019 Feb;12(1):106-109. doi: 10.1093/ckj/sfy019. Epub 2018 Mar 20.

3.

Complement Gene Variants and Shiga Toxin-Producing Escherichia coli-Associated Hemolytic Uremic Syndrome: Retrospective Genetic and Clinical Study.

Frémeaux-Bacchi V, Sellier-Leclerc AL, Vieira-Martins P, Limou S, Kwon T, Lahoche A, Novo R, Llanas B, Nobili F, Roussey G, Cailliez M, Ulinski T, Deschênes G, Alberti C, Weill FX, Mariani P, Loirat C.

Clin J Am Soc Nephrol. 2019 Mar 7;14(3):364-377. doi: 10.2215/CJN.05830518. Epub 2019 Jan 23.

PMID:
30674459
4.

Anticomplement Treatment in Atypical and Typical Hemolytic Uremic Syndrome.

Fakhouri F, Loirat C.

Semin Hematol. 2018 Jul;55(3):150-158. doi: 10.1053/j.seminhematol.2018.04.009. Epub 2018 Apr 20. Review.

PMID:
30032752
5.

Patterns of Clinical Response to Eculizumab in Patients With C3 Glomerulopathy.

Le Quintrec M, Lapeyraque AL, Lionet A, Sellier-Leclerc AL, Delmas Y, Baudouin V, Daugas E, Decramer S, Tricot L, Cailliez M, Dubot P, Servais A, Mourey-Epron C, Pourcine F, Loirat C, Frémeaux-Bacchi V, Fakhouri F.

Am J Kidney Dis. 2018 Jul;72(1):84-92. doi: 10.1053/j.ajkd.2017.11.019. Epub 2018 Feb 9.

PMID:
29429752
6.

Hemolytic uremic syndrome due to Shiga toxin-producing Escherichia coli infection.

Bruyand M, Mariani-Kurkdjian P, Gouali M, de Valk H, King LA, Le Hello S, Bonacorsi S, Loirat C.

Med Mal Infect. 2018 May;48(3):167-174. doi: 10.1016/j.medmal.2017.09.012. Epub 2017 Oct 18. Review.

PMID:
29054297
7.

[Hemolytic and uremic syndrome and related thrombotic microangiopathies: Treatment and prognosis].

Rafat C, Coppo P, Fakhouri F, Frémeaux-Bacchi V, Loirat C, Zuber J, Rondeau E.

Rev Med Interne. 2017 Dec;38(12):833-839. doi: 10.1016/j.revmed.2017.07.005. Epub 2017 Sep 22. Review. French.

PMID:
28947259
8.

[Hemolytic and uremic syndrome and related thrombotic microangiopathies: Epidemiology, pathophysiology and clinics].

Rafat C, Coppo P, Fakhouri F, Frémeaux-Bacchi V, Loirat C, Zuber J, Rondeau E.

Rev Med Interne. 2017 Dec;38(12):817-824. doi: 10.1016/j.revmed.2017.06.004. Epub 2017 Jul 12. Review. French.

PMID:
28711159
9.

Hemolytic Uremic Syndrome in Pregnancy and Postpartum.

Bruel A, Kavanagh D, Noris M, Delmas Y, Wong EKS, Bresin E, Provôt F, Brocklebank V, Mele C, Remuzzi G, Loirat C, Frémeaux-Bacchi V, Fakhouri F.

Clin J Am Soc Nephrol. 2017 Aug 7;12(8):1237-1247. doi: 10.2215/CJN.00280117. Epub 2017 Jun 8.

10.

[Well-being in adulthood of patients with chronic conditions in childhood: The GEDEPAC-2 questionnaire].

Mellerio H, Dumas A, Guilmin-Crépon S, Loirat C, Lévy-Marchal C, Audard V, de Vathaire F, Alberti C.

Rev Epidemiol Sante Publique. 2017 Apr;65(2):137-148. doi: 10.1016/j.respe.2017.01.001. Epub 2017 Feb 27. French.

PMID:
28245953
11.

Haemolytic uraemic syndrome.

Fakhouri F, Zuber J, Frémeaux-Bacchi V, Loirat C.

Lancet. 2017 Aug 12;390(10095):681-696. doi: 10.1016/S0140-6736(17)30062-4. Epub 2017 Feb 25. Review. Erratum in: Lancet. 2017 Aug 12;390(10095):648.

PMID:
28242109
12.

[Improving the quality of life of residents].

Ben Makhad M, Faucheux-Bourdon C, Guibe A, Tortevois A, Morel C, Loirat C, Bonnain A.

Rev Infirm. 2017 Jan;66(227):25-26. doi: 10.1016/j.revinf.2016.11.009. French.

PMID:
28048988
13.

Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation.

Fakhouri F, Fila M, Provôt F, Delmas Y, Barbet C, Châtelet V, Rafat C, Cailliez M, Hogan J, Servais A, Karras A, Makdassi R, Louillet F, Coindre JP, Rondeau E, Loirat C, Frémeaux-Bacchi V.

Clin J Am Soc Nephrol. 2017 Jan 6;12(1):50-59. doi: 10.2215/CJN.06440616. Epub 2016 Oct 31.

14.

Child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a cohort study of the French national registry for thrombotic microangiopathy.

Joly BS, Stepanian A, Leblanc T, Hajage D, Chambost H, Harambat J, Fouyssac F, Guigonis V, Leverger G, Ulinski T, Kwon T, Loirat C, Coppo P, Veyradier A; French Reference Center for Thrombotic Microangiopathies.

Lancet Haematol. 2016 Nov;3(11):e537-e546. doi: 10.1016/S2352-3026(16)30125-9. Epub 2016 Oct 3.

PMID:
27720178
15.

Observations of a large Dent disease cohort.

Blanchard A, Curis E, Guyon-Roger T, Kahila D, Treard C, Baudouin V, Bérard E, Champion G, Cochat P, Dubourg J, de la Faille R, Devuyst O, Deschenes G, Fischbach M, Harambat J, Houillier P, Karras A, Knebelmann B, Lavocat MP, Loirat C, Merieau E, Niaudet P, Nobili F, Novo R, Salomon R, Ulinski T, Jeunemaître X, Vargas-Poussou R.

Kidney Int. 2016 Aug;90(2):430-439. doi: 10.1016/j.kint.2016.04.022. Epub 2016 Jun 22.

PMID:
27342959
16.

Mutation Update of the CLCN5 Gene Responsible for Dent Disease 1.

Mansour-Hendili L, Blanchard A, Le Pottier N, Roncelin I, Lourdel S, Treard C, González W, Vergara-Jaque A, Morin G, Colin E, Holder-Espinasse M, Bacchetta J, Baudouin V, Benoit S, Bérard E, Bourdat-Michel G, Bouchireb K, Burtey S, Cailliez M, Cardon G, Cartery C, Champion G, Chauveau D, Cochat P, Dahan K, De la Faille R, Debray FG, Dehoux L, Deschenes G, Desport E, Devuyst O, Dieguez S, Emma F, Fischbach M, Fouque D, Fourcade J, François H, Gilbert-Dussardier B, Hannedouche T, Houillier P, Izzedine H, Janner M, Karras A, Knebelmann B, Lavocat MP, Lemoine S, Leroy V, Loirat C, Macher MA, Martin-Coignard D, Morin D, Niaudet P, Nivet H, Nobili F, Novo R, Faivre L, Rigothier C, Roussey-Kesler G, Salomon R, Schleich A, Sellier-Leclerc AL, Soulami K, Tiple A, Ulinski T, Vanhille P, Van Regemorter N, Jeunemaître X, Vargas-Poussou R.

Hum Mutat. 2015 Aug;36(8):743-52. doi: 10.1002/humu.22804. Epub 2015 Jun 11. Review.

PMID:
25907713
17.

An international consensus approach to the management of atypical hemolytic uremic syndrome in children.

Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre A, Coppo R, Emma F, Johnson S, Karpman D, Landau D, Langman CB, Lapeyraque AL, Licht C, Nester C, Pecoraro C, Riedl M, van de Kar NC, Van de Walle J, Vivarelli M, Frémeaux-Bacchi V; HUS International.

Pediatr Nephrol. 2016 Jan;31(1):15-39. doi: 10.1007/s00467-015-3076-8. Epub 2015 Apr 11. Review.

PMID:
25859752
18.

Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies.

Licht C, Greenbaum LA, Muus P, Babu S, Bedrosian CL, Cohen DJ, Delmas Y, Douglas K, Furman RR, Gaber OA, Goodship T, Herthelius M, Hourmant M, Legendre CM, Remuzzi G, Sheerin N, Trivelli A, Loirat C.

Kidney Int. 2015 May;87(5):1061-73. doi: 10.1038/ki.2014.423. Epub 2015 Feb 4.

19.

An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndrome.

Johnson S, Stojanovic J, Ariceta G, Bitzan M, Besbas N, Frieling M, Karpman D, Landau D, Langman C, Licht C, Pecoraro C, Riedl M, Siomou E, van de Kar N, Walle JV, Loirat C, Taylor CM.

Pediatr Nephrol. 2014 Oct;29(10):1967-78. doi: 10.1007/s00467-014-2817-4. Epub 2014 May 11.

PMID:
24817340
20.

Anti-factor H autoantibody-associated hemolytic uremic syndrome: the earlier diagnosed and treated, the better.

Loirat C, Frémeaux-Bacchi V.

Kidney Int. 2014 May;85(5):1019-22. doi: 10.1038/ki.2013.447.

21.

A new gel formulation of topical cysteamine for the treatment of corneal cystine crystals in cystinosis: the Cystadrops OCT-1 study.

Labbé A, Baudouin C, Deschênes G, Loirat C, Charbit M, Guest G, Niaudet P.

Mol Genet Metab. 2014 Mar;111(3):314-320. doi: 10.1016/j.ymgme.2013.12.298. Epub 2014 Jan 9.

PMID:
24440466
22.

Macrovascular involvement in a child with atypical hemolytic uremic syndrome.

Ažukaitis K, Loirat C, Malina M, Adomaitienė I, Jankauskienė A.

Pediatr Nephrol. 2014 Jul;29(7):1273-7. doi: 10.1007/s00467-013-2713-3. Epub 2013 Dec 19.

PMID:
24352218
23.

[Adult socioprofessional status of childhood kidney transplant recipients].

Loirat C, Mellerio H, Labéguerie M, Andriss B, Savoye E, Lassalle M, Jacquelinet C, Alberti C.

Bull Acad Natl Med. 2013 Nov;197(8):1607-8. French. No abstract available.

PMID:
26021180
24.

Adult social and professional outcomes of pediatric renal transplant recipients.

Mellerio H, Alberti C, Labèguerie M, Andriss B, Savoye E, Lassalle M, Jacquelinet C, Loirat C; French Working Group on the Long-Term Outcome of Transplanted Children.

Transplantation. 2014 Jan 27;97(2):196-205. doi: 10.1097/TP.0b013e3182a74de2.

PMID:
24092383
25.

Eculizumab in atypical hemolytic-uremic syndrome.

Legendre CM, Licht C, Loirat C.

N Engl J Med. 2013 Oct 3;369(14):1379-80. doi: 10.1056/NEJMc1308826. No abstract available.

PMID:
24088105
26.

Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases.

Fakhouri F, Delmas Y, Provot F, Barbet C, Karras A, Makdassi R, Courivaud C, Rifard K, Servais A, Allard C, Besson V, Cousin M, Châtelet V, Goujon JM, Coindre JP, Laurent G, Loirat C, Frémeaux-Bacchi V.

Am J Kidney Dis. 2014 Jan;63(1):40-8. doi: 10.1053/j.ajkd.2013.07.011. Epub 2013 Sep 8.

PMID:
24021908
27.

Targeted strategies in the prevention and management of atypical HUS recurrence after kidney transplantation.

Zuber J, Le Quintrec M, Morris H, Frémeaux-Bacchi V, Loirat C, Legendre C.

Transplant Rev (Orlando). 2013 Oct;27(4):117-25. doi: 10.1016/j.trre.2013.07.003. Epub 2013 Aug 12. Review.

PMID:
23937869
28.

Erratum: Post-partum atypical haemolytic-uraemic syndrome treated with eculizumab: terminal complement activity assessment in clinical practice.

Delmas Y, Bordes C, Loirat C, Frémeaux-Bacchi V, Combe C.

Clin Kidney J. 2013 Aug;6(4):454. doi: 10.1093/ckj/sft098.

29.

[Hemolytic uremic syndrome as of 2013].

Loirat C, Mariani-Kurkdjian P, Fremeaux-Bacchi V.

Arch Pediatr. 2013 Aug;20(8):827-30. doi: 10.1016/j.arcped.2013.05.015. Epub 2013 Jul 5. French. No abstract available.

PMID:
23835098
30.

Atypical hemolytic uremic syndrome: from the rediscovery of complement to targeted therapy.

Fakhouri F, Frémeaux-Bacchi V, Loirat C.

Eur J Intern Med. 2013 Sep;24(6):492-5. doi: 10.1016/j.ejim.2013.05.008. Epub 2013 Jun 5. Review.

PMID:
23756030
31.

Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.

Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nürnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C.

N Engl J Med. 2013 Jun 6;368(23):2169-81. doi: 10.1056/NEJMoa1208981.

32.

Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome.

Lemaire M, Frémeaux-Bacchi V, Schaefer F, Choi M, Tang WH, Le Quintrec M, Fakhouri F, Taque S, Nobili F, Martinez F, Ji W, Overton JD, Mane SM, Nürnberg G, Altmüller J, Thiele H, Morin D, Deschenes G, Baudouin V, Llanas B, Collard L, Majid MA, Simkova E, Nürnberg P, Rioux-Leclerc N, Moeckel GW, Gubler MC, Hwa J, Loirat C, Lifton RP.

Nat Genet. 2013 May;45(5):531-6. doi: 10.1038/ng.2590. Epub 2013 Mar 31.

33.

Post-partum atypical haemolytic-uraemic syndrome treated with eculizumab: terminal complement activity assessment in clinical practice.

Delmas Y, Bordes C, Loirat C, Frémeaux-Bacchi V, Combe C.

Clin Kidney J. 2013 Apr;6(2):243-4. doi: 10.1093/ckj/sfs185. No abstract available. Erratum in: Clin Kidney J. 2013 Aug;6(4):454.

34.

[Hemolytic uremic syndrome caused by Shiga-toxin-producing Escherichia coli].

Loirat C.

Rev Prat. 2013 Jan;63(1):11-6. Review. French.

PMID:
23457821
35.

Thrombotic thrombocytopenic purpura in children.

Loirat C, Coppo P, Veyradier A.

Curr Opin Pediatr. 2013 Apr;25(2):216-24. doi: 10.1097/MOP.0b013e32835e7888. Review.

PMID:
23422353
36.

Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome.

Le Quintrec M, Zuber J, Moulin B, Kamar N, Jablonski M, Lionet A, Chatelet V, Mousson C, Mourad G, Bridoux F, Cassuto E, Loirat C, Rondeau E, Delahousse M, Frémeaux-Bacchi V.

Am J Transplant. 2013 Mar;13(3):663-75. doi: 10.1111/ajt.12077. Epub 2013 Jan 28.

37.

Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults.

Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaimé F, Dragon-Durey MA, Ngo S, Moulin B, Servais A, Provot F, Rostaing L, Burtey S, Niaudet P, Deschênes G, Lebranchu Y, Zuber J, Loirat C.

Clin J Am Soc Nephrol. 2013 Apr;8(4):554-62. doi: 10.2215/CJN.04760512. Epub 2013 Jan 10.

38.

Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies.

Zuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V; French Study Group for aHUS/C3G.

Nat Rev Nephrol. 2012 Nov;8(11):643-57. doi: 10.1038/nrneph.2012.214. Epub 2012 Oct 2. Review.

PMID:
23026949
39.

Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation.

Zuber J, Le Quintrec M, Krid S, Bertoye C, Gueutin V, Lahoche A, Heyne N, Ardissino G, Chatelet V, Noël LH, Hourmant M, Niaudet P, Frémeaux-Bacchi V, Rondeau E, Legendre C, Loirat C; French Study Group for Atypical HUS.

Am J Transplant. 2012 Dec;12(12):3337-54. doi: 10.1111/j.1600-6143.2012.04252.x. Epub 2012 Sep 7.

40.

Overall neutralization of complement factor H by autoantibodies in the acute phase of the autoimmune form of atypical hemolytic uremic syndrome.

Blanc C, Roumenina LT, Ashraf Y, Hyvärinen S, Sethi SK, Ranchin B, Niaudet P, Loirat C, Gulati A, Bagga A, Fridman WH, Sautès-Fridman C, Jokiranta TS, Frémeaux-Bacchi V, Dragon-Durey MA.

J Immunol. 2012 Oct 1;189(7):3528-37. Epub 2012 Aug 24.

41.

Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura.

Lotta LA, Wu HM, Mackie IJ, Noris M, Veyradier A, Scully MA, Remuzzi G, Coppo P, Liesner R, Donadelli R, Loirat C, Gibbs RA, Horne A, Yang S, Garagiola I, Musallam KM, Peyvandi F.

Blood. 2012 Jul 12;120(2):440-8. doi: 10.1182/blood-2012-01-403113. Epub 2012 Apr 23.

42.

Management of hemolytic uremic syndrome.

Loirat C, Saland J, Bitzan M.

Presse Med. 2012 Mar;41(3 Pt 2):e115-35. doi: 10.1016/j.lpm.2011.11.013. Epub 2012 Jan 27.

PMID:
22284541
43.

Spectrum of mutations in the renin-angiotensin system genes in autosomal recessive renal tubular dysgenesis.

Gribouval O, Morinière V, Pawtowski A, Arrondel C, Sallinen SL, Saloranta C, Clericuzio C, Viot G, Tantau J, Blesson S, Cloarec S, Machet MC, Chitayat D, Thauvin C, Laurent N, Sampson JR, Bernstein JA, Clemenson A, Prieur F, Daniel L, Levy-Mozziconacci A, Lachlan K, Alessandri JL, Cartault F, Rivière JP, Picard N, Baumann C, Delezoide AL, Belar Ortega M, Chassaing N, Labrune P, Yu S, Firth H, Wellesley D, Bitzan M, Alfares A, Braverman N, Krogh L, Tolmie J, Gaspar H, Doray B, Majore S, Bonneau D, Triau S, Loirat C, David A, Bartholdi D, Peleg A, Brackman D, Stone R, DeBerardinis R, Corvol P, Michaud A, Antignac C, Gubler MC.

Hum Mutat. 2012 Feb;33(2):316-26. doi: 10.1002/humu.21661. Epub 2011 Dec 22. Review.

PMID:
22095942
44.

Kidney and liver transplantation in patients with autosomal recessive polycystic kidney disease: a multicentric study.

Chapal M, Debout A, Dufay A, Salomon R, Roussey G, Burtey S, Launay EA, Vigneau C, Blancho G, Loirat C, Hourmant M, Fakhouri F.

Nephrol Dial Transplant. 2012 May;27(5):2083-8. doi: 10.1093/ndt/gfr588. Epub 2011 Nov 9.

PMID:
22076432
45.

Mycophenolate mofetil for steroid-dependent nephrotic syndrome: a phase II Bayesian trial.

Baudouin V, Alberti C, Lapeyraque AL, Bensman A, André JL, Broux F, Cailliez M, Decramer S, Niaudet P, Deschênes G, Jacqz-Aigrain E, Loirat C.

Pediatr Nephrol. 2012 Mar;27(3):389-96. doi: 10.1007/s00467-011-2006-7. Epub 2011 Sep 28.

PMID:
21947272
46.

Atypical hemolytic uremic syndrome.

Loirat C, Frémeaux-Bacchi V.

Orphanet J Rare Dis. 2011 Sep 8;6:60. doi: 10.1186/1750-1172-6-60. Review.

47.

Cyclophosphamide in steroid-dependent nephrotic syndrome.

Azib S, Macher MA, Kwon T, Dechartres A, Alberti C, Loirat C, Deschênes G, Baudouin V.

Pediatr Nephrol. 2011 Jun;26(6):927-32. doi: 10.1007/s00467-011-1830-0. Epub 2011 Mar 12.

PMID:
21394465
48.

[Atypical hemolytic-uremic syndrome related to abnormalities within the complement system].

Frémeaux-Bacchi V, Fakhouri F, Roumenina L, Dragon-Durey MA, Loirat C.

Rev Med Interne. 2011 Apr;32(4):232-40. doi: 10.1016/j.revmed.2009.09.039. Epub 2011 Mar 3. French.

49.

Alternative complement pathway assessment in patients with atypical HUS.

Roumenina LT, Loirat C, Dragon-Durey MA, Halbwachs-Mecarelli L, Sautes-Fridman C, Fremeaux-Bacchi V.

J Immunol Methods. 2011 Feb 28;365(1-2):8-26. doi: 10.1016/j.jim.2010.12.020. Epub 2011 Jan 6. Review.

PMID:
21215749
50.

Membranoproliferative glomerulonephritis with C3NeF and genetic complement dysregulation.

Leroy V, Fremeaux-Bacchi V, Peuchmaur M, Baudouin V, Deschênes G, Macher MA, Loirat C.

Pediatr Nephrol. 2011 Mar;26(3):419-24. doi: 10.1007/s00467-010-1734-4. Epub 2010 Dec 25.

PMID:
21188423

Supplemental Content

Loading ...
Support Center